Track market-moving stories before they get noisy

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference on Lung Cancer (WCLC). The conference is hosted by the International Association for the Study of Lung Cancer (IAS.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with ESR1 mutations before radiographic progression who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca's next-gener.

Callan Family Office LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 6,080 shares of the company’s stock, valued at approximately $912,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of GH. Orbimed Advisors LLC acquired a new stake in Guardant Health in the 1st quarter valued at about $40,199,000. World Investment Advisors acquired a new stake in Guardant Health in the fourth quarter valued at approximately $1,664,000. GSA Capital Partners LLP purchased a new position in Guardant Health in the second quarter worth approximately $1,772,000. Ninepoint Partners LP purchased a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $2,853,000. Finally, SWS Partners acquired a new stake in shares of Guardant Health in the 2nd quarter valued at $11,190,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Guardant Health In other news, insider Terilyn J. Monroe sold 46,300 shares of Guardant Health stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total value of $7,645,056.00. Following the transaction, the insider directly owned 22,979 shares of the company’s stock, valued at $3,794,292.48. The trade was a 66.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. This trade represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 559,318 shares of company stock valued at $83,882,733. 5.60% of the stock is owned by company insiders.

Guardant Health Stock Down 4.4% NASDAQ:GH opened at $163.18 on Tuesday. The company has a market capitalization of $21.90 billion, a PE ratio of -46.76 and a beta of 1.60. Guardant Health, Inc. has a 52-week low of $53.40 and a 52-week high of $176.58. The stock’s 50 day moving average price is $154.58 and its 200 day moving average price is $119.07. Guardant Health (NASDAQ:GH – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. Guardant Health’s quarterly revenue was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.44) EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Analysts Set New Price Targets A number of analysts have weighed in on the company. Piper Sandler raised their price target on Guardant Health from $135.00 to $193.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Wolfe Research assumed coverage on Guardant Health in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. Bank of America boosted their target price on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. TD Cowen upped their price target on Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. upped their price target on Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

Get Our Latest Stock Analysis on Guardant Health

Guardant Health Profile (Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Further Reading Five stocks we like better than Guardant Health Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.

On August 24, 2026, Guardant Health Inc
GH -4.42% 65

shares fell 4.4% to a current price of $163.18, reflecting a volatile trading environment. The stock has experienced a 52-week range of $53.40 to $176.58, underscoring significant fluctuations throughout the year.

GF Value™ verdict: Current price is $163.18 vs GF Value™ of $65.51, indicating a 149.1% overvaluation.GF Score™: 65/100, suggesting an above-average rating.Notable signal: Insider activity shows a net selling of $182.1M over the past year, indicating a cautious outlook from insiders.Is GH Overvalued or Undervalued?According to the GF Value™, which is GuruFocus' proprietary estimate of intrinsic value derived from historical trading multiples and future performance estimates, Guardant Health Inc is significantly overvalued at its current price of $163.18 compared to the GF Value™ of $65.51. This represents a substantial margin of safety for potential investors, as the current price exceeds the estimated fair value by 149.1%. Such a large disparity serves as a directional warning to investors, suggesting that the stock may be priced too high given its cash-flow-negative status.

The GF Valuation label indicates that GH is in a significantly overvalued category, raising concerns about the sustainability of its current price levels. With earnings still negative, traditional earnings-based valuation methods like Price-to-Earnings (P/E) ratios do not apply effectively, further reinforcing the reliance on Price-to-Sales (P/S) analysis. Historically, GH has traded at a median P/S of approximately 14.2x, which sets a critical benchmark for evaluating its current valuation. Given this context, the risk of continued price correction is elevated, as market sentiment may not sustain such high valuations without corresponding improvements in financial performance.

How Does GH's Valuation Compare to Its History?Unfortunately, due to the company's unprofitable status, traditional P/E ratio metrics are not applicable. Therefore, a direct comparison with its historical valuation through the P/E framework is not feasible. However, utilizing the P/S analysis can provide insights into whether the stock is trading above or below its historical valuation norms.

MetricCurrentHistoricalP/S RatioUnknown~14.2xWithout concrete P/E data, it is prudent to focus on the P/S analysis, which indicates that GH may be trading at a premium compared to its historical valuation. Hence, this suggests alignment with the GF Value™ verdict that GH is significantly overvalued at present.

What Does GH's GF Score™ Tell Us?The GF Score™ is a comprehensive measure that evaluates a company's financial strength, profitability, growth potential, valuation, and momentum. Guardant Health's score of 65/100 reflects an above-average standing, with the strongest sub-rank being growth at 10/10 and the weakest being valuation at 1/10.

MetricRatingGF Score™65Financial Strength4/10Profitability3/10Growth10/10Valuation1/10Momentum6/10The overall scores provide a mixed picture for GH. While the high growth rank indicates potential for future expansion, the low valuation rank highlights significant concerns regarding its current pricing relative to intrinsic value. The financial strength and profitability ranks also reflect weaknesses that could challenge the company in maintaining investor confidence.

What Are Gurus and Insiders Doing with GH?Currently, 8 gurus hold shares of Guardant Health, with 5 increasing their positions and 4 trimming their holdings in recent quarters. This activity signals a mixed sentiment among institutional investors, which could be indicative of uncertainty regarding the company’s future prospects.

Insider trading has been notably bearish over the past year, with insiders selling $182.2M in stock while only purchasing $0.1M. This net selling of $182.1M suggests a lack of confidence from those closest to the company, which adds an additional layer of concern for potential investors. The disparity between insider selling and buying could imply that insiders may not believe the stock is currently a good value.

What This Means for InvestorsIn conclusion, Guardant Health Inc is currently overvalued based on the GF Value™ estimate, which suggests that the stock's price is significantly above its intrinsic value. The combination of heavy insider selling, a low valuation rank, and the cash-flow-negative status of the company raises several red flags for potential investors. Those interested in the stock should remain cautious and consider the implications of the current valuations before proceeding. For further insights, please visit the Guardant Health Inc
GH -4.42% 65

stock page to explore additional information and analysis.

Frequently Asked QuestionsWhat is GH's GF Score™?

GH has a GF Score™ of 65/100, indicating an above-average rating, suggesting that while the company has potential, there are significant areas of concern, particularly in valuation.

Is GH overvalued or undervalued?

GH is currently overvalued according to the GF Value™ estimate, which indicates that the stock price is significantly higher than its intrinsic value.

What is GH's P/E ratio?

GH does not have a P/E ratio due to its unprofitable status, making it challenging to assess traditional valuation metrics. Instead, the focus should be on P/S analysis for valuation insights.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

-

Current Guardant Reveal, Shield products excluded from final District Court orderCompany has validated Guardant360 design improvements to exclude impact of potential royalties PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal.

“We strongly disagree with this decision and will promptly be appealing for its overturn,” said John Saia, Guardant Health Chief Legal Officer. “We have full faith in the strengths and merits of Guardant’s intellectual property and R&D and are confident we will ultimately prevail on appeal.”

Importantly, the order published on Friday regarding the scope of royalties expressly defined the products included as those that existed at the time of the trial in 2023, many of which have been discontinued or significantly upgraded. Based on Guardant’s updated technology the current versions of Guardant Reveal and Shield are excluded from the order and potential royalties. In addition, the company has validated design improvements to Guardant360 and related services that would exclude impact of the potential ongoing royalties in the decision.

Guardant remains confident that it did not infringe the asserted patents. Both TwinStrand patents have been preliminarily invalidated in the company’s ongoing challenges before the U.S. Patent and Trademark Office. Separately, Guardant is pursuing appeals before the U.S. Court of Appeals for the Federal Circuit.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

More News From Guardant Health, Inc.

Back to Newsroom

4 Healthcare Stocks With Massive Gains—and More to ComeGuardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.

Eltoukhy said the company’s second-quarter performance reflected “a business that’s really firing on all cylinders,” citing three large and overlapping growth opportunities in therapy selection, recurrence detection and cancer screening. He said Guardant360, the company’s liquid-biopsy therapy selection test, delivered more than 30% year-over-year growth, while its tissue test grew at an even faster rate.

Get Guardant Health alerts:

Deciphering Disruption: Inside Cathie Wood's Latest PlaysAccording to Eltoukhy, adoption of the company’s Smart Platform, which combines genomic and epigenomic capabilities, has supported volume growth in both liquid and tissue testing. He said the platform’s applications and performance have helped differentiate Guardant360 Liquid CDx, including its ability to identify certain disease characteristics and transitions in lung cancer from blood samples.

MRD portfolio expands with Reveal Ultra
Guardant’s MRD business, centered on its Guardant Reveal test, grew more than 100% year over year, Eltoukhy said. The company launched a therapy-monitoring indication for Reveal in November, and he said the business is benefiting from Guardant’s established relationships with oncologists through Guardant360.

3 Fast-Growing Stocks Analysts See Doubling in PriceThe company expects to launch Guardant Reveal Ultra, its first tumor-informed offering, during 2026. Eltoukhy said the addition would give Guardant a broad oncology testing portfolio spanning liquid, tissue, tumor-informed and tissue-free approaches.

He described tumor-informed and tissue-free MRD testing as complementary opportunities. Tissue-free testing can provide results more quickly and may identify disease beyond the tissue removed in surgery, while tumor-informed approaches can offer deeper sensitivity, he said. Guardant believes both approaches will be important across what Eltoukhy characterized as an approximately 18 million-patient MRD market.

Guardant is pursuing reimbursement progress for Reveal in breast cancer and therapy monitoring through MolDX, Eltoukhy said. He added that demand has been strong even before reimbursement, which he viewed as evidence of product-market fit. The company is also working toward eventual ADLT, or advanced diagnostic laboratory test, status for Reveal and its tissue products, potentially through regulatory pathways.

Shield adoption and payer coverage
Talasaz said Shield, Guardant’s blood-based colorectal cancer screening test, has moved from a category-building phase into a category-scaling phase. Shield recorded roughly 50% quarter-over-quarter volume growth and multi-hundred-percent year-over-year growth, according to Eltoukhy.

Talasaz said adoption by healthcare providers and primary-care physicians, as well as sales-representative productivity, has exceeded the company’s expectations. He also pointed to UnitedHealth Group’s decision to provide broad coverage for Shield for eligible patients in its plans.

Guardant had worked with UnitedHealth for several years, including pilots involving employer populations managed by the insurer, Talasaz said. He said recent colorectal cancer screening guideline inclusion, including by the American Cancer Society, served as a final catalyst for UnitedHealth’s coverage decision.

While the company is holding constructive discussions with other payers, Talasaz said Guardant does not expect another major payer coverage decision before the end of 2026. He added that the American Cancer Society guideline may also support state-level coverage mandates in certain states.

Cost reductions and screening pipeline
Guardant received FDA approval for an enhanced Shield workflow designed to increase laboratory throughput and efficiency. Talasaz said the workflow is expected to lower Shield’s cost of goods sold by 15% by year-end. He said the company is targeting Shield cost of goods sold of about $200 at scale in 2028, compared with approximately $400 reported in the second quarter, while projecting an average selling price above $700 at that point.

The company has more than 400 commercial representatives in the field and plans to expand that organization to between 600 and 700 representatives at steady state, Talasaz said. Guardant is also running national direct-to-consumer and influencer campaigns, although most commercial investment remains focused on field-based promotion.

Shield was developed as a multi-cancer detection platform and has been clinically validated for a panel of 10 solid tumor types, Talasaz said. While it is FDA approved for colorectal cancer screening, Guardant is also conducting a lung cancer screening study. Enrollment has been completed, and the company expects to complete clinical follow-up and the database sometime before year-end or in early 2027.

Guardant also offers patients receiving Shield for colorectal cancer screening the option to receive information on nine additional cancer types through its data initiative program. Talasaz said the majority of primary-care physicians ordering Shield are opting into those multi-cancer reports. The resulting commercial database could ultimately support a future FDA submission to expand Shield’s indication from colorectal cancer screening to multi-cancer detection, he said.

Reimbursement and longer-term opportunities
Eltoukhy said Guardant360 Liquid CDx’s recent FDA approval did not materially affect second-quarter results because the company is phasing its launch. Guardant expects the principal launch to occur after obtaining ADLT designation, which Eltoukhy said has been positioned as a first-half 2027 event. The process includes securing a PLA code and then submitting for ADLT status.

He said broader reimbursement for the therapy-selection test would likely occur in stages, beginning with Medicare Part B, followed by Medicare Advantage and commercial payers, in a process that could take 12 to 24 months.

Beyond oncology, Talasaz said Guardant’s epigenomic technologies have generated early proof-of-concept findings in areas including organ health monitoring, fatty liver disease and neurodegenerative diseases such as Alzheimer’s disease and dementia. He stressed that these efforts remain in early stages, but said the company sees potential to apply its oncology model of screening, monitoring and treatment management in other disease areas.

About Guardant Health (NASDAQ:GH)Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Guardant Health Right Now?Before you consider Guardant Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.

While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs.

Posted by Defense World Staff on Aug 8th, 2026

Dimensional Fund Advisors LP lowered its position in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 40.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 182,727 shares of the company’s stock after selling 123,826 shares during the quarter. Dimensional Fund Advisors LP owned about 0.14% of Guardant Health worth $16,857,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. First Pacific Financial increased its stake in Guardant Health by 33.1% in the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after acquiring an additional 139 shares during the last quarter. Xponance LLC raised its stake in Guardant Health by 2.1% during the fourth quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after purchasing an additional 199 shares in the last quarter. Danske Bank A S lifted its position in Guardant Health by 20.0% during the fourth quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after purchasing an additional 200 shares during the last quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna lifted its position in Guardant Health by 1.9% during the fourth quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock valued at $1,124,000 after purchasing an additional 200 shares during the last quarter. Finally, Wealthfront Advisers LLC lifted its position in Guardant Health by 7.2% during the first quarter. Wealthfront Advisers LLC now owns 3,042 shares of the company’s stock valued at $281,000 after purchasing an additional 204 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health In related news, insider Chris Freeman sold 24,406 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the completion of the transaction, the insider owned 60,034 shares in the company, valued at $7,124,234.78. The trade was a 28.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 724,445 shares of company stock worth $93,089,291. 5.60% of the stock is owned by corporate insiders.

Guardant Health Trading Up 6.9% Shares of NASDAQ:GH opened at $168.48 on Friday. The company has a market capitalization of $22.61 billion, a PE ratio of -48.27 and a beta of 1.60. Guardant Health, Inc. has a 12-month low of $51.44 and a 12-month high of $176.58. The business’s fifty day simple moving average is $147.02 and its 200-day simple moving average is $115.20.

Analysts Set New Price Targets A number of research firms have recently weighed in on GH. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Barclays increased their price target on shares of Guardant Health from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. Canaccord Genuity Group boosted their price objective on Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Guggenheim upped their price objective on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $183.78.

Get Our Latest Report on GH

Guardant Health Profile (Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Featured Stories Five stocks we like better than Guardant Health Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDimensional Fund Advisors LP Boosts Stake in Mayville Engineering Company, Inc. $MEC

NEXT HEADLINE »Dimensional Fund Advisors LP Purchases 138,708 Shares of Diversified Healthcare Trust $DHC

+ GuruFocus.com on

AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA”, the “Company” or the “Group”) said Q2 2026 free cash flow* rose 36% year-on-year to $727m, further strengthening its balance sheet and providing for increased shareholder returns. The Company reaffirmed its 2026 annual guidance.(6)

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731433108/en/

“This result shows the strong cash generation capacity of our assets, and the resilience of our portfolio,” said CEO Alberto Calderon. “We remain focused on managing the factors in our control to optimise margins as we look to a production increase in the second half of the year.”

An interim dividend for Q2 2026 was declared of $364m, or 72 US cents per share. This takes the dividend declared for H1 2026 to $949m, or 188 US cents per share, compared to $469m, or 92.5 US cents per share declared in H1 2025. A proposed $2bn share buyback programme was approved by the Company’s shareholders on 23 July 2026.

AngloGold Ashanti continues to focus on a series of key strategic initiatives: delivery of predictable operating results; providing competitive returns to shareholders; bringing a large, new production centre into operation in southern Nevada in the United States; the steady ramp-up of its Obuasi mine in Ghana; and realising organic growth projects at its mines in Tanzania, Guinea, Egypt and Brazil.

Earnings, free cash flow* increase even after tax payments more than double

Cash flows continued to be robust in Q2 2026, underpinned by the steady operating performance. Cash generated from operations for Q2 2026 rose 49% to $1.8bn, compared with $1.2bn in Q2 2025, demonstrating the robust performance of the portfolio.

As expected, cash taxes for Q2 2026 more than doubled year-over-year to $542m, from $237m in Q2 2025, representing the higher gold price and improved profitability as well as timing of tax payments across the operating jurisdictions. Remaining 2026 cash taxes(3) are expected to be paid in equal quarterly instalments of between $230m to $250m.

Headline earnings(4) increased 58% year-on-year to $1.0bn in Q2 2026 from $639m in Q2 2025, and EBITDA*(5) rose 46% year-on-year to $2.0bn in Q2 2026, from $1.4bn in Q2 2025, supported by continued focus on cost management and a 35% increase year-on-year in the average gold price received per ounce*(1) to $4,446/oz.

Distributions to non-controlling interests of $234m in Q2 2026 were also markedly higher versus $150m in Q2 2025 and $162m in Q1 2026.

Free cash flow* for H1 2026 more than doubled year-on-year to $1.9bn.

Balance sheet supports disciplined capital allocation

The Group’s balance sheet strengthened significantly as a result of the growth in free cash flow*, ending H1 2026 with net cash*(5) of $991m, reversing the net debt*(5) position of $311m at 30 June 2025.

On 16 April 2026, the Group completed the repurchase of approximately $666m principal amount of its outstanding bonds. This bond buyback has reduced gross debt, lowered future interest obligations, and partially eliminated maturities in 2028 and 2030, enhancing financial flexibility through the cycle.

To further optimise capital allocation, on 23 July 2026, the Company’s shareholders approved a proposed share repurchase programme for up to $2.0bn of AngloGold Ashanti’s ordinary shares. This programme is expected to provide the Company with an additional mechanism for shareholder returns, alongside the existing dividend framework, aligning AngloGold Ashanti’s capital allocation with its North American peer group. Crucially, the Group retains ample capacity to continue investing in safe, stable operations and funding its pipeline of high-return organic growth projects.

Steady production performance

Gold production for the Group(1)(2) was 744,000oz in Q2 2026 compared to 804,000oz in Q2 2025, mainly reflecting the sale of Serra Grande in December 2025, lower production at Obuasi as a result of the previously reported contractor fatality in April 2026, and planned mine sequencing and maintenance across certain operations. H2 2026 production is expected to be higher than in H1 2026.

Underlying operational costs down $20/oz at managed operations(1) partially offsetting macro headwinds

The Company’s continued focus on rigorous cost discipline held total cash costs per ounce* for managed operations(1) at $1,431/oz for H1 2026. External pressures included a $93/oz rise in royalties due to higher realised gold prices, $60/oz in inflationary impacts, specifically related to higher labour and mining contractor costs, a $50/oz impact from foreign exchange movements and the follow-on impact of rising oil price contributed a further $20/oz increase in costs. Crucially, structural efficiencies delivered through the Full Asset Potential programme reduced underlying, controllable costs by $20/oz in H1 2026 compared to H1 2025.

Total cash costs per ounce* for the Group(1) rose to $1,480/oz in Q2 2026 from $1,226/oz in Q2 2025, predominantly driven by macroeconomic market factors representing a $216/oz increase, while operational factors contributed $29/oz.

The external factors included: general inflation (average CPI) linked mainly to increases in labour and mining contractor costs (+$71/oz); higher gold-price-linked royalties (+$67/oz); and elevated fuel prices ($43/oz), reflecting the 45% increase in average Brent crude prices as the Company prioritised fuel supply security during the ongoing US-Iran conflict. Foreign exchange headwinds added $35/oz, driven primarily by the year-on-year strengthening of the Australian dollar (+10%), Brazilian real (+11%) and Ghanaian cedi (+9%) against the US dollar.

Management remains focused on the cost drivers within its control. The Group’s Full Asset Potential programme and broader operational-improvement initiatives remain central to protecting margins and improving the efficiency and resilience of the portfolio.

All-in sustaining costs per ounce* (“AISC”) for the Group(1) were $2,039/oz in Q2 2026 compared with $1,666/oz in Q2 2025. The increase was mainly driven by the impact of lower gold sales and higher sustaining capital expenditure*, which rose to $332m in Q2 2026, from $273m in Q2 2025.

The Company increased its investment in Mineral Reserve development and mine life extensions, and advanced its pipeline of organic greenfield and brownfield growth projects.

Non-sustaining capital expenditure* doubled to $217m in Q2 2026, from $108m in Q2 2025.

Momentum and resilience at managed operations

The tragic fatality of a contractor on 24 April 2026 at the Obuasi mine in Ghana was previously reported along with the Q1 2026 results in May. An investigation into the incident has been completed and work is underway to implement corrective actions.

The Total Recordable Injury Frequency Rate (“TRIFR”) at the Company’s managed operations improved to 0.79 injuries per million hours worked in Q2 2026 compared to 0.86 injuries per million hours worked in Q1 2026.

Unlocking value from within the portfolio

AngloGold Ashanti has undertaken an in-depth review of its portfolio to identify opportunities to create additional value from its current suite of operating assets. The Group has identified a pipeline of high-return, capital-efficient brownfield opportunities with the potential to increase gold production from 2029 onwards.

These opportunities span mining, processing and recovery improvements at Obuasi, Geita, Sukari, Siguiri and Cuiabá. The strategy is focused on leveraging existing infrastructure and ore bodies to bring forward potentially high-return ounces from existing assets. Work is also underway to advance the longer-term, Tier One growth opportunities from the North Bullfrog and Arthur Gold projects in Nevada.

“We have two major advantages – world class greenfield growth projects in Nevada, and a wealth of untapped value right inside our existing mines,” said CEO Alberto Calderon. “Our priority is to unlock it, boosting production, extending life and lowering unit costs by expanding capacity and using the infrastructure we already have in place. This high-return brownfield growth is anticipated to be highly efficient.”

Guidance on track with an improved H2 2026(6)

Gold production is expected to be significantly weighted toward H2 2026. As production volumes increase, unit costs are expected to trend lower during H2 2026. Full-year 2026 guidance for gold production, costs and capital expenditure, which was issued in February 2026, remains unchanged.

(1)

The term “managed operations” refers to subsidiaries managed by AngloGold Ashanti and included in its consolidated reporting, while the term “non-managed joint ventures” (i.e., Kibali) refers to equity-accounted joint ventures that are reported based on AngloGold Ashanti's share of attributable earnings and are not managed by AngloGold Ashanti.Managed operations are reported on a consolidated basis. Non-managed joint ventures are reported on an attributable basis.

(2)

Includes gold concentrate from the Cuiabá mine sold to third parties.

(3)

Subject to macroeconomic factors, primarily realised gold prices. Tax payment estimates reflect consensus market gold price forecasts for the remainder of 2026 and are subject to change.

(4)

The financial measures “headline earnings (loss)” and “headline earnings (loss) per share” are not calculated in accordance with IFRS® Accounting Standards, but in accordance with the Headline Earnings Circular 1/2023, issued by the South African Institute of Chartered Accountants (SAICA), at the request of the Johannesburg Stock Exchange Limited (JSE).

These measures are required to be disclosed by the JSE Listings Requirements and therefore do not constitute Non-GAAP financial measures for purposes of the rules and regulations of the US Securities and Exchange Commission (“SEC”) applicable to the use and disclosure of Non-GAAP financial measures.

(5)

To enhance comparability with industry peers, AngloGold Ashanti will present net debt (cash)* and EBITDA* as well as its net debt (cash)* to EBITDA* ratio (leverage ratio), which are Non-GAAP financial measures, and will not further adjust these metrics in its reporting. Comparative periods will also reflect this change.

(6)

Estimates assume neither operational or labour interruptions or power disruptions, nor further changes to asset portfolio and/or operating mines and have not been reviewed by AngloGold Ashanti’s external auditors. Other unknown or unpredictable factors, or factors outside the Company’s control, including inflationary pressures on its cost base, could also have material adverse effects on AngloGold Ashanti’s future results and no assurance can be given that any expectations expressed by AngloGold Ashanti will prove to have been correct. Measures taken at AngloGold Ashanti’s operations together with AngloGold Ashanti’s business continuity plans aim to enable its operations to deliver in line with its production targets. Actual results could differ from guidance and any deviations may be significant. Please refer to the Risk Factors section in AngloGold Ashanti’s annual report on Form 20-F for the financial year ended 31 December 2025 filed with the SEC.

*

Refer to “Non-GAAP disclosure” in the Full Announcement for definitions and reconciliations.

Key statistics

Quarter

Quarter

Six months

Six months

ended

ended

ended

ended

Jun

Jun

Jun

Jun

US Dollar millions, except as otherwise noted

2026

2025

2026

2025

Operating review

Gold

Produced - Group(1)(2)(3)

- oz (000)

744

804

1,468

1,524

Produced - Managed operations(1)(2)(3)

- oz (000)

668

729

1,334

1,386

Produced - Non-managed joint ventures(1)

- oz (000)

76

75

134

138

Sold - Group(1)(2)(3)

- oz (000)

753

801

1,472

1,538

Sold - Managed operations(1)(2)(3)

- oz (000)

682

732

1,332

1,403

Sold - Non-managed joint ventures(1)

- oz (000)

71

69

140

135

Financial review

Gold income

- $m

3,034

2,407

6,188

4,334

Cost of sales - Group(1)

- $m

1,528

1,355

2,944

2,585

Cost of sales - Managed operations(1)

- $m

1,401

1,248

2,694

2,372

Cost of sales - Non-managed joint ventures(1)

- $m

127

107

250

213

Total operating costs

- $m

1,063

942

2,062

1,775

Gross profit

- $m

1,703

1,197

3,646

2,036

Average gold price received per ounce* - Group(1)

- $/oz

4,446

3,287

4,650

3,089

Average gold price received per ounce* - Managed operations(1)

- $/oz

4,448

3,287

4,647

3,090

Average gold price received per ounce* - Non-managed joint ventures(1)

- $/oz

4,431

3,285

4,672

3,078

All-in sustaining costs per ounce* - Group(1)

- $/oz

2,039

1,666

1,998

1,654

All-in sustaining costs per ounce* - Managed operations(1)

- $/oz

2,073

1,694

2,027

1,676

All-in sustaining costs per ounce* - Non-managed joint ventures(1)

- $/oz

1,710

1,367

1,715

1,414

Total cash costs per ounce* - Group(1)

- $/oz

1,480

1,226

1,436

1,224

Total cash costs per ounce* - Managed operations(1)

- $/oz

1,486

1,241

1,431

1,228

Total cash costs per ounce* - Non-managed joint ventures(1)

- $/oz

1,426

1,081

1,482

1,193

Profit for the period

- $m

1,192

806

3,609

1,775

EBITDA*(5)

- $m

1,974

1,353

4,265

2,349

Total borrowings

- $m

1,778

2,297

1,778

2,297

Net debt (cash)*(5)

- $m

(991)

311

(991)

(624)

Profit attributable to equity shareholders

- $m

1,002

669

2,283

1,112

- US cents/share

197

132

448

219

Headline earnings(4)

- $m

1,010

639

2,295

1,087

- US cents/share

198

125

451

214

Net cash inflow from operating activities

- $m

1,432

1,018

3,141

1,743

Free cash flow*

- $m

727

535

1,895

938

Capital expenditure - Group(1)

- $m

549

381

1,016

717

Capital expenditure - Managed operations(1)

- $m

487

350

915

653

Capital expenditure - Non-managed joint ventures(1)

- $m

62

31

101

64

(1)

The term “managed operations” refers to subsidiaries managed by AngloGold Ashanti and included in its consolidated reporting, while the term “non-managed joint ventures” (i.e., Kibali) refers to equity-accounted joint ventures that are reported based on AngloGold Ashanti’s share of attributable earnings and are not managed by AngloGold Ashanti. Managed operations are reported on a consolidated basis. Non-managed joint ventures are reported on an attributable basis.

(2)

Includes gold concentrate from the Cuiabá mine sold to third parties In Q2 2026 and H1 2026.

(3)

Includes gold production and gold sold for the Serra Grande operation, which was sold on 1 December 2025, comprising 16,000oz for Q2 2025 and 26,000oz for H1 2025.

(4)

The financial measures “headline earnings (loss)” and “headline earnings (loss) per share” are not calculated in accordance with IFRS® Accounting Standards, but in accordance with the Headline Earnings Circular 1/2023, issued by the South African Institute of Chartered Accountants (SAICA), at the request of the Johannesburg Stock Exchange Limited (JSE). These measures are required to be disclosed by the JSE Listings Requirements and therefore do not constitute Non-GAAP financial measures for purposes of the rules and regulations of the US Securities and Exchange Commission (“SEC”) applicable to the use and disclosure of Non-GAAP financial measures.

(5)

To enhance comparability with industry peers, AngloGold Ashanti will present net debt (cash)* and EBITDA* as well as its net debt (cash)* to EBITDA* ratio (leverage ratio), which are Non-GAAP financial measures, and will not further adjust these metrics in its reporting. Comparative periods will also reflect this change.

*

Refer to “Non-GAAP disclosure” in the Full Announcement for definitions and reconciliations.

$ represents US Dollar, unless otherwise stated.

Rounding of figures may result in computational discrepancies.

AngloGold Ashanti plc today announces an interim dividend for the three months ended 30 June 2026 of 72 US cents per share. In respect of the interim dividend, the timelines, including dates for currency conversions, set out below will apply.

To holders of ordinary shares on the New York Stock Exchange (NYSE)

2026

Ex-dividend on NYSE

Friday, 21 August

Record date

Friday, 21 August

Payment date

Friday, 4 September

To holders of ordinary shares on the South African Register

Additional information for South African resident shareholders of AngloGold Ashanti:

Shareholders registered on the South African section of the register are advised that the distribution of 72 US cents per ordinary share will be converted to South African rands at the applicable exchange rate.

In compliance with the requirements of Strate and the Johannesburg Stock Exchange (JSE) Listings Requirements, the salient dates for payment of the dividend are as follows:

2026

Declaration date

Friday, 31 July

Currency conversion rate for South African rands announcement date

Friday, 14 August

Last date to trade ordinary shares cum dividend

Tuesday, 18 August

Ordinary shares trade ex-dividend

Wednesday, 19 August

Record date

Friday, 21 August

Payment date

Friday, 4 September

Dividends in respect of dematerialised shareholdings will be credited to shareholders’ accounts with the relevant CSDP (as defined below) or broker.

To comply with further requirements of Strate, share certificates may not be dematerialised or rematerialised between Wednesday, 19 August 2026 and Friday, 21 August 2026, both days inclusive. No transfers between South African, NYSE and Ghanaian share registers will be permitted between Friday, 14 August 2026 and Friday, 21 August 2026, both days inclusive.

Details of the exchange rates applicable to the dividend and a summary of the tax considerations applicable to South African shareholders is expected to be published on Friday, 14 August 2026.

To Beneficial Owners on the Ghana sub-register holding shares through the nominee arrangement with the Central Securities Depositary (GH) LTD

2026

Currency conversion date

Friday, 14 August

Last date to trade and to register shares cum dividend

Tuesday, 18 August

Shares trade ex-dividend

Wednesday, 19 August

Record date

Friday, 21 August

Approximate payment date of dividend

Friday, 4 September

To Beneficial Owners holding Ghanaian Depositary Shares (GhDSs) and acting by National Trust Holding Company Ltd as depository agent 100 GhDSs represent one ordinary share

2026

Currency conversion date

Friday, 14 August

Last date to trade and to register GhDSs cum dividend

Tuesday, 18 August

GhDSs trade ex-dividend

Wednesday, 19 August

Record date

Friday, 21 August

Approximate payment date of dividend

Friday, 4 September

Beneficial owners on the Ghana sub-register holding shares and beneficial owners holding GhDSs are advised that the distribution of 72 US cents per ordinary share will be converted to Ghanaian cedis at the applicable exchange rate. Assuming an exchange rate of US$X/ ¢11.6600, the gross dividend payable per share, is equivalent to ca. ¢8.3952 Ghanaian cedis. However, the actual rate of payment will depend on the exchange rate on the date for currency conversion.

Entitlement to interim dividends

A “Shareholder of Record” is a person appearing on the register of members of the Company in respect of ordinary shares at the close of business on the relevant record date. A “Beneficial Owner” is a person who holds ordinary shares of the Company through a bank, broker, central securities depository participant (“CSDP”), Shareholder of Record or other agent (sometimes referred to as holding shares “in street name”).

AngloGold Ashanti plc
(Incorporated in England and Wales)
Registration No. 14654651
LEI No. 2138005YDSA7A82RNU96
ISIN: GB00BRXH2664
CUSIP: G0378L100
NYSE Share code: AU
JSE Share code: ANG
A2X Share code: ANG
GhSE (Shares): AGA
GhSE (GhDS): AAD

Johannesburg, South Africa
31 July 2026
JSE Sponsor: The Standard Bank of South Africa Limited

Forward-looking statements

Certain statements contained in this document, other than statements of historical fact, including, without limitation, those concerning the economic outlook for the gold mining industry, expectations regarding gold prices, production, mine life, total cash costs, all-in sustaining costs, cost savings and other operating results, return on equity, productivity improvements, growth prospects, preliminary financial and production metrics for in-process projects, the ability to convert Mineral Resource into Mineral Reserve and replace Mineral Reserve net of depletion from production and outlook of AngloGold Ashanti’s operations, individually or in the aggregate, including the achievement of project milestones, commencement and completion of commercial operations of certain of AngloGold Ashanti’s exploration and production projects, the completion of acquisitions, dispositions or joint venture transactions, AngloGold Ashanti’s liquidity and capital resources and capital expenditures and the outcome and consequences of any potential or pending litigation or regulatory proceedings or environmental, health and safety issues, are forward-looking statements regarding AngloGold Ashanti’s financial reports, operations, economic performance and financial condition. These forward-looking statements or forecasts are not based on historical facts, but rather reflect our current beliefs and expectations concerning future events and generally may be identified by the use of forward-looking words, phrases and expressions such as “believe”, “expect”, “aim”, “anticipate”, “intend”, “foresee”, “forecast”, “predict”, “project”, “estimate”, “likely”, “may”, “might”, “could”, “should”, “would”, “seek”, “plan”, “scheduled”, “possible”, “continue”, “potential”, “outlook”, “target” or other similar words, phrases, and expressions; provided that the absence thereof does not mean that a statement is not forward-looking. Similarly, statements that describe our objectives, plans or goals are or may be forward-looking statements. These forward-looking statements or forecasts involve known and unknown risks, uncertainties and other factors that may cause AngloGold Ashanti’s actual results, performance, actions or achievements to differ materially from the anticipated results, performance, actions or achievements expressed or implied in these forward-looking statements. Although AngloGold Ashanti believes that the expectations reflected in such forward-looking statements and forecasts are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results, performance, actions or achievements could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic, social, political and market conditions, including related to inflation or international conflicts, the success of business and operating initiatives, changes in the regulatory environment and other government actions, including environmental approvals, fluctuations in gold prices and exchange rates, the outcome of pending or future litigation proceedings, any supply chain disruptions, any public health crises, pandemics or epidemics, the failure to maintain effective internal control over financial reporting or effective disclosure controls and procedures, the inability to remediate one or more material weaknesses, or the discovery of additional material weaknesses, in the Company’s internal control over financial reporting, and other business and operational risks and challenges and other factors, including mining accidents. For a discussion of such risk factors, refer to AngloGold Ashanti’s annual report on Form 20-F for the financial year ended 31 December 2025 filed with the United States Securities and Exchange Commission (SEC). These factors are not necessarily all of the important factors that could cause AngloGold Ashanti’s actual results, performance, actions or achievements to differ materially from those expressed in any forward-looking statements. Other unknown or unpredictable factors could also have material adverse effects on AngloGold Ashanti’s future results, performance, actions or achievements. Consequently, readers are cautioned not to place undue reliance on forward-looking statements. AngloGold Ashanti undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except to the extent required by applicable law. All subsequent written or oral forward-looking statements attributable to AngloGold Ashanti or any person acting on its behalf are qualified by the cautionary statements herein.

Non-GAAP financial measures

This communication may contain certain “Non-GAAP” financial measures. AngloGold Ashanti utilises certain Non-GAAP performance measures and ratios in managing its business. Non-GAAP financial measures should be viewed in addition to, and not as an alternative for, the reported operating results or cash flow from operations or any other measures of performance prepared in accordance with IFRS. In addition, the presentation of these measures may not be comparable to similarly titled measures other companies may use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731433108/en/

Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH - Free Report) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -5.00%. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.47 per share when it actually produced a loss of $0.45, delivering a surprise of +4.26%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $334.98 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 6.01%. This compares to year-ago revenues of $232.09 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Guardant Health shares have added about 41.1% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Guardant Health?While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Guardant Health was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.28 on $339.31 million in revenues for the coming quarter and -$1.39 on $1.31 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Verastem (VSTM - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This drug developer is expected to post quarterly loss of $0.46 per share in its upcoming report, which represents a year-over-year change of -18%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Verastem's revenues are expected to be $23.15 million, up 981.8% from the year-ago quarter.

Analysts on Wall Street project that Guardant Health (GH - Free Report) will announce quarterly loss of -$0.40 per share in its forthcoming report, representing an increase of 9.1% year over year. Revenues are projected to reach $316 million, increasing 36.2% from the same quarter last year.

The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

That said, let's delve into the average estimates of some Guardant Health metrics that Wall Street analysts commonly model and monitor.

Analysts' assessment points toward 'Revenue- Oncology' reaching $211.43 million. The estimate indicates a year-over-year change of +33.2%.

The combined assessment of analysts suggests that 'Revenue- Screening' will likely reach $44.83 million. The estimate suggests a change of +202.6% year over year.

The consensus among analysts is that 'Revenue- Biopharma and data' will reach $57.89 million. The estimate suggests a change of +3.3% year over year.

The consensus estimate for 'Total tests performed (oncology tests)' stands at 89,203 . Compared to the present estimate, the company reported 64,000 in the same quarter last year.

View all Key Company Metrics for Guardant Health here>>>

Shares of Guardant Health have demonstrated returns of -4.3% over the past month compared to the Zacks S&P 500 composite's +1.9% change. With a Zacks Rank #4 (Sell), GH is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Posted by Defense World Staff on Jul 27th, 2026

Caxton Associates LLP purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 8,999 shares of the company’s stock, valued at approximately $831,000.

A number of other large investors also recently bought and sold shares of the business. Alyeska Investment Group L.P. purchased a new stake in Guardant Health in the third quarter worth $114,421,000. Price T Rowe Associates Inc. MD lifted its position in shares of Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after purchasing an additional 1,414,441 shares during the last quarter. Norges Bank purchased a new stake in shares of Guardant Health during the fourth quarter valued at $128,499,000. Summit Partners Public Asset Management LLC boosted its stake in shares of Guardant Health by 674.5% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock valued at $87,019,000 after purchasing an additional 741,958 shares during the period. Finally, Westfield Capital Management Co. LP bought a new position in shares of Guardant Health in the fourth quarter worth about $55,073,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity at Guardant Health In other Guardant Health news, Director Myrtle S. Potter sold 1,556 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $204,084.96. Following the completion of the sale, the director owned 20,971 shares in the company, valued at $2,750,556.36. This represents a 6.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the sale, the chief executive officer directly owned 2,012,919 shares in the company, valued at $254,231,669.70. This trade represents a 4.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 708,565 shares of company stock valued at $90,556,597 over the last 90 days. Insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance NASDAQ GH opened at $147.33 on Monday. The firm’s 50 day moving average price is $139.41 and its 200-day moving average price is $112.02. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $174.08. The company has a market cap of $19.54 billion, a PE ratio of -43.46 and a beta of 1.59.

Wall Street Analyst Weigh In Several research analysts recently commented on the stock. Evercore reaffirmed an “outperform” rating and issued a $200.00 price target on shares of Guardant Health in a research note on Monday, July 6th. BTIG Research boosted their price objective on shares of Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Piper Sandler set a $127.00 target price on shares of Guardant Health in a research note on Thursday, May 21st. Citigroup raised their target price on shares of Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $160.04.

Check Out Our Latest Research Report on GH

About Guardant Health (Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Recommended Stories Five stocks we like better than Guardant Health RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? These 4 Earnings Reports Expose the Market’s Growing Economic Divide Broadcom May Be the Biggest Winner From Alphabet’s Earnings Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of Nova Scotia Lowers Stock Position in Manhattan Associates, Inc. $MANH

NEXT HEADLINE »Gabelli Funds LLC Buys 132,226 Shares of Albany International Corporation $AIN

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 24.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 483,557 shares of the company’s stock after selling 156,738 shares during the period. Amova Asset Management Americas Inc. owned 0.36% of Guardant Health worth $44,608,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GH. Vanguard Group Inc. increased its stake in shares of Guardant Health by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after purchasing an additional 251,939 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after buying an additional 1,414,441 shares during the period. Franklin Resources Inc. raised its stake in Guardant Health by 14.9% in the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after buying an additional 435,232 shares during the period. Geode Capital Management LLC lifted its position in shares of Guardant Health by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after buying an additional 277,001 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in shares of Guardant Health by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after acquiring an additional 72,162 shares during the period. 92.60% of the stock is owned by institutional investors.

Insider Activity In related news, Director Meghan V. Joyce sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the transaction, the director directly owned 11,183 shares in the company, valued at approximately $1,420,017.34. This represents a 47.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 708,565 shares of company stock worth $90,556,597. Corporate insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth A number of research analysts recently weighed in on the company. Guggenheim boosted their target price on Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Wolfe Research assumed coverage on Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Piper Sandler set a $127.00 price objective on shares of Guardant Health in a report on Thursday, May 21st. Finally, Canaccord Genuity Group increased their price objective on shares of Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $160.04.

Read Our Latest Stock Analysis on Guardant Health

Guardant Health Trading Down 5.0% NASDAQ:GH opened at $148.07 on Tuesday. The stock has a 50 day simple moving average of $135.24 and a 200 day simple moving average of $110.66. The stock has a market cap of $19.63 billion, a P/E ratio of -43.68 and a beta of 1.59. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $174.08.

About Guardant Health (Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

See Also Five stocks we like better than Guardant Health The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Sells 1,207,787 Shares of DraftKings Inc. $DKNG

NEXT HEADLINE »Amova Asset Management Americas Inc. Cuts Stock Holdings in Rocket Lab Corporation $RKLB

Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

©2026 Investor’s Business Daily, LLC. All Rights Reserved.

Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction").

The Transaction was approved at a special meeting of the Gamehost Shareholders held on June 11, 2026 (the "Meeting"). The Transaction required (i) the approval of 66 2/3% of the votes cast by the Gamehost Shareholders present or represented by proxy and entitled to vote at the Meeting and (ii) the approval of a simple majority of the votes cast by the Gamehost Shareholders present or represented by proxy and entitled to vote at the Meeting other than those persons required to be excluded from such vote for the purpose of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (the "Minority Shareholders"). At the Meeting, holders of 16,444,813 Gamehost Shares were present or represented by proxy, which represented 79.52% of the outstanding Gamehost Shares. Of the votes cast at the Meeting, the resolution approving the Transaction was approved by (i) 97.78% of the votes cast by the Gamehost Shareholders, and (ii) 97.35% of the votes cast by Minority Shareholders.

The Transaction will be implemented by way of a plan of arrangement under the Business Corporations Act (Alberta) and is expected to close in June 2026, subject to customary closing conditions, including the final approval of the Court of King's Bench of Alberta and regulatory approval under applicable gaming laws.

About Gamehost

Gamehost is a corporation incorporated under the laws of the Province of Alberta with its head office located in Red Deer, Alberta. Through its subsidiary, Gamehost Limited Partnership, Gamehost owns and operates: (i) the Great Northern Casino facility located in Grande Prairie, Alberta, (ii) the Rivers Casino and Entertainment Centre located in Fort McMurray, Alberta; (iii) the Deerfoot Inn & Casino facility located in Calgary, Alberta; (iv) the Service Plus Inns & Suites hotel located in Grande Prairie, Alberta, and (v) the Encore Suites by Service Plus extended stay hotel facility located in Grande Prairie, Alberta. It also owns an investment property located in Grande Prairie, Alberta adjacent to the Service Plus Inn. For more information, visit https://gamehost.ca.

About IGP and Pure

Indigenous Gaming Partners Inc. is a gaming company established in 2024 that is focused on developing a portfolio of high-quality, market-leading casinos through strategic acquisitions and operational excellence. The partnership is comprised of five institutional First Nations - Glooscap First Nation, Millbrook First Nation, Annapolis Valley First Nation, We'koqma'q L'nue'kati, and Paqtnkek Mi'kmaw Nation - along with Sonco Gaming Inc., an experienced Canadian casino management and development company. Through its operating entity, Pure Casino Entertainment Limited Partnership, IGP owns and operates Pure Casino Edmonton, Pure Casino Yellowhead, Pure Casino Calgary and Pure Casino Lethbridge, which collectively employ more than 1,200 people and welcome millions of guests each year. IGP represents a shared vision to build meaningful Indigenous ownership in Canada's entertainment industry while delivering high-quality gaming and hospitality experiences. IGP is dedicated to setting new standards in the gaming industry while fostering prosperity for its Indigenous communities, charitable partners, and provincial stakeholders. For more information, visit www.indigenousgamingpartners.ca.

Forward-Looking Information

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws (collectively, "forward-looking information"). Forward-looking information relates to future events or future performance and is based upon management's current internal expectations, estimates, projections, assumptions and beliefs. All information other than historical fact may be forward-looking information. Words such as "seek", "plan", "continue", "expect", "intend", "believe", "anticipate", "predict", "estimate", "may", "will", "could", "potential", and other similar words that indicate events or conditions may occur are intended to identify forward-looking information. In particular, this new release contains forward-looking information pertaining to the following: (i) the anticipated cash payments to Gamehost Shareholders should the Arrangement be completed and (ii) the anticipated timing of completion of the Transaction. This forward-looking information is based on certain expectations and assumptions, including that all conditions precedent to the completion of the Transaction are satisfied on terms acceptable to each of Gamehost and Pure, each acting reasonably, that there are not any material unexpected hurdles or delays in receiving the required approvals, that each of Gamehost and Pure honour their respective obligations under the Arrangement Agreement; and that Pure has the ability to satisfy its cash payment obligation at the closing of the Transaction. By its very nature, forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Gamehost believes the expectations reflected in the forward-looking statements contained in this news release are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. Some of the risks that could cause results to differ materially from those expressed in the forward-looking information include: (i) the conditions to the completion of the Arrangement, including receipt of the required approval from the Court of King's Bench of Alberta and the required approvals under applicable gaming laws may not be satisfied or waived; (ii) the timing of the completion of the Transaction may be changed or delayed; (iii) Pure may not have sufficient funds to pay the cash consideration on closing of the Transaction or, even if it has sufficient funds, may not pay the pay the cash consideration required to close the Transaction; (iv) the Arrangement Agreement may be terminated by either party under certain circumstances, including as a result of the occurrence of a material adverse change in respect of Gamehost; and (v) if the Transaction is not completed, Gamehost Shareholders will not receive the anticipated cash consideration per share. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. These statements speak only as of the date of this news release. Except as required by law, Gamehost does not undertake any obligation to publicly update or revise any forward-looking information.

The TSX does not accept responsibility for the adequacy or accuracy of this release.

Not intended for distribution to U.S. newswire services or for dissemination in the U.S.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301309

Source: Gamehost Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights

For the three-month period ended March 31, 2026, as compared to the same period of 2025:

Reported total revenue of $301.7 million, an increase of 48%, driven by: Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% Biopharma & Data revenue of $53.0 million, an increase of 17% Screening revenue of $41.6 million, and approximately 44,000 Shield screening tests, compared to $5.7 million revenue and 9,000 tests in the prior year period Generated non-GAAP gross margin of 66%, compared to 65% for the first quarter of 2025 Recent Operating Highlights

Presented 38 abstracts at the 2026 American Association for Cancer Research Annual Meeting, highlighting the breadth and strength of the Guardant portfolio Enhanced Guardant360 Tissue capabilities with the addition of whole transcriptome profiling, expanding clinical utility Announced collaboration with Nuvalent to develop companion diagnostics in targeted cancer therapy with initial emphasis on Guardant360 Tissue Received FDA approval for Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU for ER+/HER2- ESR1 mutated advanced breast cancer Leveraged InfinityAI real-world evidence to support the approval of Daiichi Sankyo’s ENHERTU Activated direct-to-consumer and influencer campaigns during Colorectal Cancer Awareness Month to drive awareness and demand Launched nationwide, multi-year collaboration with Quest to expand access to Shield and accelerate screening adoption Launched Shield Multi-Cancer Detection (MCD) in Asia through Manulife partnership “Our first-quarter revenue increased 48% year over year, reflecting strong momentum across the Guardant portfolio,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology testing volumes continued to accelerate, reaching 86,000 in the quarter, up 47% year over year. Guardant360 Liquid and Guardant360 Tissue demonstrated significant growth, and we saw strong receptivity to our expansion into therapy response monitoring with Guardant Reveal. We believe these trends, driven by our Smart platform and InfinityAI offerings, position us well for sustained growth and for extending our leadership in precision oncology.”

“We are pleased with our progress with Shield, including strong volume momentum exiting the first quarter,” said AmirAli Talasaz, co-founder and co-CEO. “We expect sustained volume growth as we further build out our commercial infrastructure and expand collaborations with Quest and other partners. With a disciplined focus on execution as we scale, we are well positioned to broaden our reach in cancer screening and drive long-term value creation.”

First Quarter 2026 Financial Results

Revenue was $301.7 million for the first quarter of 2026, a 48% increase from $203.5 million for the corresponding prior year period. Oncology revenue grew 36% to $205.0 million for the first quarter of 2026, from $150.6 million for the corresponding prior year period, primarily driven by an increase in Oncology test volume, which grew 47% over the prior year period, and an increase in reimbursement for our oncology tests. Screening revenue grew over 600% to $41.6 million for the first quarter of 2026, from $5.7 million for the corresponding prior year period, driven primarily by an increase in Shield screening test volume, which grew to approximately 44,000 tests in the first quarter of 2026, from approximately 9,000 tests in the prior year period. The increase was also attributable to an increase in reimbursement for our Shield screening tests. Biopharma and Data revenue grew 17% to $53.0 million for the first quarter of 2026, from $45.4 million for the corresponding prior year period. Licensing and other revenue was $2.1 million for the first quarter of 2026, compared to $1.9 million for the corresponding prior year period.

Gross profit, or total revenue less cost of revenue, was $196.7 million for the first quarter of 2026, an increase of $68.0 million or 53%, from $128.7 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 65% for the first quarter of 2026, as compared to 63% for the corresponding prior year period.

Non-GAAP gross profit was $200.1 million for the first quarter of 2026, an increase of $68.8 million or 52%, from $131.3 million for the corresponding prior year period. Non-GAAP gross margin was 66% for the first quarter of 2026, as compared to 65% for the corresponding prior year period.

Operating expenses were $318.1 million for the first quarter of 2026, as compared to $239.8 million for the corresponding prior year period. Non-GAAP operating expenses were $268.1 million for the first quarter of 2026, as compared to $199.6 million for the corresponding prior year period. The year-over-year increase in both operating expenses and non-GAAP operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support the Shield and Oncology growth.

Net loss was $112.1 million for the first quarter of 2026, as compared to $95.2 million for the corresponding prior year period. Net loss per share was $0.85 for the first quarter of 2026, as compared to $0.77 for the corresponding prior year period.

Non-GAAP net loss was $58.7 million for the first quarter of 2026, as compared to $61.1 million for the corresponding prior year period. Non-GAAP net loss per share was $0.45 for the first quarter of 2026, as compared to $0.49 for the corresponding prior year period.

Adjusted EBITDA loss was $58.9 million for the first quarter of 2026, as compared to a $58.5 million loss for the corresponding prior year period.

Free cash flow for the first quarter of 2026 was $(71.2) million, as compared to $(67.1) million for the corresponding prior year period.

Cash, cash equivalents, restricted cash and marketable securities were $1.2 billion as of March 31, 2026.

2026 Guidance

Guardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32 billion, representing growth of 32% to 34% compared to full year 2025. This compares to the prior range of $1.25 to $1.28 billion, representing growth of 27% to 30%.

Within this revenue range:

Oncology revenue is now expected to grow in the range of 28% to 29% in 2026, compared to prior guidance of 25% to 27%. Oncology volume is now expected to grow greater than 35% in 2026, compared to prior guidance of approximately 30%. Guardant Health continues to expect Biopharma & Data revenue growth to be in the low double-digit range. Screening revenue is now expected to be in the range of $186 to $198 million, driven by Shield volume of 230,000 to 245,000 tests. This compares to the prior guidance of $162 to $174 million revenue and 210,000 to 225,000 tests. Guardant Health continues to expect full year 2026 non-GAAP gross margin to be in the range of 64% to 65%. Guardant Health now expects total non-GAAP operating expenses to be in the range of $1.05 to $1.07 billion, an increase compared to the prior range of $1.03 to $1.05 billion. Guardant Health continues to expect free cash flow burn to be in the range of $185 to $195 million, an improvement compared to $233 million for the full year 2025.

Webcast Information

Guardant Health will host a conference call to discuss the first quarter 2026 financial results after market close on Thursday, May 7, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event.

Non-GAAP Measures

Guardant Health has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA, and free cash flow.

We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax payments, contingent consideration, amortization of intangible assets, impairment of non-marketable equity securities, gain on extinguishment of convertible notes, and other non-recurring items.

Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax payments; contingent consideration; and other non-recurring items. Free cash flow is defined as net cash used in operating activities in the period less purchases of property and equipment in the period.

We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain items because we believe that these income and expenses do not reflect expected future operating performance. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.

These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

  Guardant Health, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share data)

  Three Months Ended March 31,

2026

2025

Revenue

$

301,665

$

203,471

Costs and operating expenses:

Cost of revenue

104,919

74,723

Research and development expense

91,038

88,521

Sales and marketing expense

169,132

104,316

General and administrative expense

57,926

46,952

Total costs and operating expenses

423,015

314,512

Loss from operations

(121,350

)

(111,041

)

Interest income

11,151

9,112

Interest expense

(1,347

)

(791

)

Other income (expense), net

(157

)

7,851

Loss before provision for income taxes

(111,703

)

(94,869

)

Provision for income taxes

372

290

Net loss

$

(112,075

)

$

(95,159

)

Net loss per share, basic and diluted

$

(0.85

)

$

(0.77

)

Weighted-average shares used in computing net loss per share, basic and diluted

131,273

123,871

  Guardant Health, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share data)

  March 31, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$

989,291

$

378,203

Short-term marketable securities

113,469

823,395

Accounts receivable, net

137,404

137,849

Inventory, net

83,851

85,876

Prepaid expenses and other current assets, net

43,490

40,723

Total current assets

1,367,505

1,466,046

Restricted cash

112,150

111,214

Property and equipment, net

150,035

145,915

Right-of-use assets, net

153,906

158,849

Intangible assets, net

25,543

25,921

Goodwill

77,257

77,257

Other assets, net

28,895

28,457

Total Assets

$

1,915,291

$

2,013,659

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current liabilities:

Accounts payable

$

75,034

$

54,442

Accrued compensation

91,326

119,646

Accrued expenses

78,013

77,889

Deferred revenue

47,772

50,753

Total current liabilities

292,145

302,730

Convertible senior notes, net

1,503,471

1,504,000

Long-term operating lease liabilities

173,055

178,463

Other long-term liabilities

127,693

127,773

Total Liabilities

2,096,364

2,112,966

Stockholders’ deficit:

Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 131,514,404 and 130,635,301 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

1

1

Additional paid-in capital

2,930,665

2,900,056

Accumulated other comprehensive loss

(5,152

)

(4,852

)

Accumulated deficit

(3,106,587

)

(2,994,512

)

Total Stockholders’ Deficit

(181,073

)

(99,307

)

Total Liabilities and Stockholders’ Deficit

$

1,915,291

$

2,013,659

  Guardant Health, Inc.

Supplemental Revenue Information

(unaudited)

(in thousands)

  Three Months Ended March 31,

2026

2025

Oncology

$

204,954

$

150,559

Biopharma and data

52,977

45,376

Screening

41,590

5,677

Licensing and other

2,144

1,859

Total revenue

$

301,665

$

203,471

  Reconciliation of Selected GAAP Measures to Non-GAAP Measures

(unaudited)

(in thousands, except per share data)

  Three Months Ended March 31,

2026

2025

GAAP cost of revenue

$

104,919

$

74,723

Amortization of intangible assets

(148

)

(148

)

Stock-based compensation expense and related employer payroll tax payments

(3,211

)

(2,390

)

Non-GAAP cost of revenue

$

101,560

$

72,185

GAAP gross profit

$

196,746

$

128,748

Amortization of intangible assets

148

148

Stock-based compensation expense and related employer payroll tax payments

3,211

2,390

Non-GAAP gross profit

$

200,105

$

131,286

GAAP research and development expense

$

91,038

$

88,521

Stock-based compensation expense and related employer payroll tax payments

(14,449

)

(13,090

)

Contingent consideration

—

(534

)

Non-GAAP research and development expense

$

76,589

$

74,897

GAAP sales and marketing expense

$

169,132

$

104,316

Stock-based compensation expense and related employer payroll tax payments

(14,702

)

(10,189

)

Non-GAAP sales and marketing expense

$

154,430

$

94,127

GAAP general and administrative expense

$

57,926

$

46,952

Amortization of intangible assets

(230

)

(332

)

Stock-based compensation expense and related employer payroll tax payments

(19,509

)

(13,571

)

Contingent consideration

—

(490

)

Other

(1,150

)

(2,000

)

Non-GAAP general and administrative expense

$

37,037

$

30,559

Three Months Ended March 31,

2026

2025

GAAP loss from operations

$

(121,350

)

$

(111,041

)

Amortization of intangible assets

378

480

Stock-based compensation expense and related employer payroll tax payments

51,871

39,240

Contingent consideration

—

1,024

Other

1,150

2,000

Non-GAAP loss from operations

$

(67,951

)

$

(68,297

)

GAAP net loss

$

(112,075

)

$

(95,159

)

Amortization of intangible assets

378

480

Stock-based compensation expense and related employer payroll tax payments

51,871

39,240

Contingent consideration

—

1,024

Impairment of non-marketable equity securities

—

5,000

Gain on extinguishment of convertible notes

—

(13,672

)

Other

1,150

2,000

Non-GAAP net loss

$

(58,676

)

$

(61,087

)

GAAP net loss per share, basic and diluted

$

(0.85

)

$

(0.77

)

Non-GAAP net loss per share, basic and diluted

$

(0.45

)

$

(0.49

)

Weighted-average shares used in computing GAAP and Non-GAAP net loss per share, basic and diluted

131,273

123,871

  Reconciliation of GAAP Net Loss to Adjusted EBITDA

(unaudited)

(in thousands)

  Three Months Ended March 31,

2026

2025

GAAP net loss

$

(112,075

)

$

(95,159

)

Interest income

(11,151

)

(9,112

)

Interest expense

1,347

791

Other expense (income), net

157

(7,851

)

Provision for income taxes

372

290

Depreciation and amortization

9,442

10,236

Stock-based compensation expense and related employer payroll tax payments

51,871

39,240

Contingent consideration

—

1,024

Other

1,150

2,000

Adjusted EBITDA

$

(58,887

)

$

(58,541

)

  Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities

(unaudited)

(in thousands)

  Three Months Ended March 31,

2026

2025

Net cash used in operating activities

$

(65,623

)

$

(62,689

)

Purchases of property and equipment

(5,580

)

(4,459

)

Free cash flow

$

(71,203

)

$

(67,148

)

More News From Guardant Health, Inc.

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs w.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardan

The approval also transfers the seven previously approved companion diagnostic indications from Guardant360 CDx to the updated test.

The cancer testing company said Guardant360 Liquid CDx is now the largest FDA-approved liquid biopsy panel and evaluates a genomic footprint that is 100 times wider than the earlier Guardant360 CDx test.

The test combines genomic and epigenomic insights from a single blood sample to help clinicians make more informed treatment decisions.

New Platform Integrates Genomic And Epigenomic InsightsGuardant said the updated test is powered by its proprietary Smart Platform, an AI-enabled multiomic technology platform designed to improve circulating tumor DNA detection sensitivity compared with the previous Guardant360 CDx test.

According to the company, the platform integrates genomic and epigenomic profiling from one blood draw, helping identify clinically actionable information that may not be detected through genomics alone.

Faster Turnaround Time And Expanded Clinical UtilityGuardant said the updated liquid biopsy test can deliver results in as little as seven days. The company noted the test is designed to support treatment selection decisions regardless of tissue availability, therapy line, or practice setting.

The company also stated that Guardant360 Liquid CDx is the first liquid biopsy capable of simultaneously identifying genotype and key phenotype information.

Guardant added that its full oncology testing portfolio has now transitioned to the Smart Platform, which supports multiple cancer care applications across the treatment continuum using a single scalable testing infrastructure.

Price ActionGuardant Health shares were up 8.81% at $106.84 at the time of publication on Wednesday, according to Benzinga Pro.

Over the past month, GH has gained about 10.6% versus a 4.3% rise in the S&P 500 and is down roughly 2% year-to-date compared to the index’s 7.8% gain.

Photo by Tada Images via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated Ameri

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026.

Key data that will be presented include:

Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, marking the world’s largest FDA-approved liquid biopsy panel, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations. Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Demonstrating advanced detection missed by standard genomic methods, the analysis demonstrated improved detection of actionable ALK fusions in non-small cell lung cancer (NSCLC) while maintaining high specificity by identifying additional ALK fusion-positive cases. Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval. “Our presence at this year’s ASCO reflects the power of liquid biopsy tests to provide oncologists with actionable insights to more effectively treat patients in a faster amount of time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant’s Smart Platform, an AI-enabled multiomic technology platform behind our next generation of cancer tests, is fueling the entire portfolio and supporting new clinical applications across the cancer care continuum.”

Key Guardant Health and collaborator presentations at ASCO 2026

Presentation

Title

Time / Location

8502

Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study

May 29, 2026 / 1:00 - 4:00 PM CDT

3525 / 279

A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance)

May 30, 2026 / 9:00 AM - 12:00 PM CDT

3546 / 313

A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in NeoRAS wild-type metastatic colorectal cancer patients (C-PROWESS)

May 30, 2026 / 9:00 AM - 12:00 PM CDT

3572 / 339

Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer

May 30, 2026 / 9:00 AM - 12:00 PM CDT

3659 / 426

Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD)

May 30, 2026 / 9:00 AM - 12:00 PM CDT

4050 / 33

Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)

May 30, 2026 / 9:00 AM - 12:00 PM CDT

4159 / 142

First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected FGFR2 fusion-positive advanced cholangiocarcinoma: a real-world analysis

May 30, 2026 / 9:00 AM - 12:00 PM CDT

4161 / 144

Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP

May 30, 2026 / 9:00 AM - 12:00 PM CDT

4238 / 221

Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy

May 30, 2026 / 9:00 AM - 12:00 PM CDT

3051 / 188

Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME)

May 30, 2026 / 1:30 - 4:30 PM CDT

3052 / 189

Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: a real-world study

May 30, 2026 / 1:30 - 4:30 PM CDT

3070 / 207

Cell-free DNA methylation profile-based fusion epigenotyping to enhance ALK fusion detection in NSCLC patients

May 30, 2026 / 1:30 - 4:30 PM CDT

3077 / 214

Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling

May 30, 2026 / 1:30 - 4:30 PM CDT

3105 / 242

Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M)

May 30, 2026 / 1:30 - 4:30 PM CDT

1031 / 145

Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer

June 1, 2026 / 1:30 - 4:30 PM CDT

1095 / 209

Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i)

June 1, 2026 / 1:30 - 4:30 PM CDT

The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2026 can be found on the ASCO website.

About Guardant360® Liquid CDx

The largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic data for comprehensive insights. Guardant360 Liquid CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives.

About Guardant360 Liquid

Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.

About Guardant Reveal

Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.

The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.

About Shield

Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

More News From Guardant Health, Inc.